Comparative Pharmacology
Head-to-head clinical analysis: MYCOBUTIN versus RIFAMPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCOBUTIN versus RIFAMPIN.
MYCOBUTIN vs RIFAMPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA-dependent RNA polymerase in Mycobacterium tuberculosis, blocking RNA synthesis.
Inhibits DNA-dependent RNA polymerase in bacteria, blocking RNA synthesis.
300 mg orally once daily, or 300 mg twice weekly for MAC prophylaxis in HIV. For TB, 300 mg daily as part of combination therapy.
Oral or IV: 600 mg once daily (10 mg/kg/day). For tuberculosis: 10 mg/kg (max 600 mg) once daily.
None Documented
None Documented
Terminal elimination half-life: 35-40 hours (range 30-50 hours). Clinical context: Allows once-daily dosing; prolonged in hepatic or renal impairment.
Terminal elimination half-life is 3–5 hours initially, decreasing to 2–3 hours after repeated dosing due to autoinduction of hepatic microsomal enzymes. In hepatic impairment, half-life may increase to 5–8 hours.
Renal (30% as unchanged drug), fecal (50-60% as metabolites and parent compound), biliary (minor).
Biliary excretion of unchanged drug (60–65%) and metabolites (15–20%); renal excretion of unchanged drug (15–20%) and metabolites (5–10%); fecal elimination of unabsorbed drug (≤5%).
Category C
Category A/B
Antimycobacterial
Antimycobacterial